# The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia

## TL;DR

This paper reviews recent updates in classifying and predicting outcomes for a specific type of leukemia caused by a genetic abnormality.

## Contribution

The paper summarizes the latest classification and prognosis criteria for BCR::ABL1 positive ALL introduced in 2022 and 2023.

## Key findings

- New WHO and ICC classifications were updated in 2022 for BCR::ABL1 positive ALL.
- NCCN introduced prognosis factors in 2023, including minimal residual disease and IKZF1plus gene typing.
- These updates are expected to significantly impact clinical diagnosis and treatment strategies.

## Abstract

酪氨酸激酶抑制剂和免疫靶向药物的应用已经明显改变了BCR::ABL1阳性急性B淋巴细胞白血病的治疗策略和临床结果。2022年，世界卫生组织（WHO）和国际共识分型（ICC）相继对该疾病的分型进行了更新。2023年，美国国立综合癌症网络（NCCN）也首次更新了该疾病的预后分层，其治疗后的微小残留病评估和IKZF1plus基因分型是最关键的预后因素。以上更新将对临床诊疗产生重大影响，本文聚焦于该疾病分型和预后评估的最新更新内容展开综述。